Dingdang Health Tech Grp Ltd (9886) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Dingdang Health Tech Grp Ltd HK$2.37, price HK$0.80, upside +196.3%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Dingdang Health Tech Grp Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
49‑month range HK$0.3300 – HK$12.58 · fair‑value band HK$1.55 – HK$3.56 · the HK$0.8000 price screens below the HK$2.37 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Follow Dingdang Health Tech Grp in your weekly email
Every Wednesday you see whether Dingdang Health Tech Grp is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dingdang Health Technology Group Ltd. provides digital healthcare services in the People's Republic of China. The company offers online medical consultation through online and supplementary services; chronic diseases and health management; health portfolio management and DOT medication adherence services.
Show more
Dingdang Health Technology Group Ltd. provides digital healthcare services in the People's Republic of China. The company offers online medical consultation through online and supplementary services; chronic diseases and health management; health portfolio management and DOT medication adherence services. It provides a range of health products through offline retail and online direct sales channels. Dingdang Health Technology Group Ltd. was incorporated in 2014 and is headquartered in Beijing, China.
Stock analysis
Dingdang Health Tech Grp Ltd (9886) currently trades at HK$0.8000, while our model-based Fair Value estimate is HK$2.37, implying the stock looks roughly 66.2% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$2.50 per share, and 11 of the 11 models we run sit above the HK$0.8000 price.
Bear case: the Asset-Based group reads lowest at HK$1.05, and 0 of the 11 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$1.55 (bear) to HK$3.56 (bull), the price of HK$0.8000 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Dingdang Health Tech Grp Ltd reported revenue of 4.9B CNY in FY2025 versus 3.7B CNY in FY2021, a compound +7.4%/yr. Reported net income was −49.0M CNY in FY2025.
Key figures
Market cap HK$1.0B (≈ $128M) · P/S ratio 0.20 · Net margin −1.0% · Return on equity −4.1% · Return on assets (EBIT) −9.3% · Operating margin 0.2% · Revenue (TTM) 5.0B CNY · Revenue growth (YoY) +3.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 196%, 9886 screens cheaper than that median.
Fair Value models
Bear HK$1.55Fair Value HK$2.37Bull HK$3.56
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.7%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.9% (2020) → −1.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Compare Dingdang Health Tech Grp Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 130 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score63 · Above median
Fair Value upside+191.3% · Top 25%
Profitability
Return on assets−1.2% · Below median
Net margin (TTM)−1.0% · Below median
Operating margin (TTM)0.3% · Below median
Growth and dividend
Revenue growth6.7% · Below median
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Dingdang Health Tech Grp Ltd Fair Value". https://www.fairvalue-calculator.com/stock/9886
Frequently asked questions
Is Dingdang Health Tech Grp Ltd (9886) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of HK$2.37 versus a price of HK$0.8000, about +196% upside (undervalued).
What is the fair value of 9886?
Our model-based fair value for Dingdang Health Tech Grp Ltd is HK$2.37 (as of Oct 2, 2026), built from audited fundamentals. The current price: HK$0.8000.
What is the quality score of 9886?
Dingdang Health Tech Grp Ltd has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dingdang Health Tech Grp Ltd (9886)?
Our model-based price target is the fair value of HK$2.37 (as of Oct 2, 2026) from 11 valuation models. Cautious scenario HK$1.55, optimistic scenario HK$3.56. It is a calculation from audited fundamentals, not an analyst target.
What is the Dingdang Health Tech Grp Ltd stock forecast for 2026?
Our models put fair value at HK$2.37, about +196% upside versus a price of HK$0.8000 (undervalued). Cautious scenario HK$1.55, optimistic scenario HK$3.56. The calculation is refreshed regularly with new filings.
What is the revenue of Dingdang Health Tech Grp Ltd (9886)?
Dingdang Health Tech Grp Ltd reported trailing-twelve-month revenue of about 5.0B CNY (latest available figure, as of Oct 2, 2026).
What growth is priced into Dingdang Health Tech Grp Ltd (9886)?
For today's price to be fair in a discounted-cash-flow model, Dingdang Health Tech Grp Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.0 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 9886 use?
Our models discount Dingdang Health Tech Grp Ltd at 13.1 %: a base by market capitalisation (micro), damped by beta 0.96, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dingdang Health Tech Grp Ltd that is less than minus 40 % per year a year over ten years, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has Dingdang Health Tech Grp Ltd (9886) delivered so far?
Over the past 5 years revenue at Dingdang Health Tech Grp Ltd grew +17.0 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dingdang Health Tech Grp Ltd (9886) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Dingdang Health Tech Grp Ltd (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dingdang Health Tech Grp Ltd (9886)?
The free-cash-flow yield on the price is 14.25 %: that much free cash flow Dingdang Health Tech Grp Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dingdang Health Tech Grp Ltd (9886)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dingdang Health Tech Grp Ltd it is HK$2.37 per share (as of Oct 2, 2026), against a price of HK$0.8000. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Dingdang Health Tech Grp Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 9886 trades below its calculated fair value: price HK$0.8000, fair value HK$2.37, a gap of about +196% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9886?
No. The price is what the market pays today (HK$0.8000); the fair value is what the company's own numbers justify (HK$2.37). For Dingdang Health Tech Grp Ltd the two are HK$1.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dingdang Health Tech Grp Ltd worth?
The market values Dingdang Health Tech Grp Ltd at about HK$1.0B (market capitalisation, as of Oct 2, 2026). Per share that is HK$0.8000; our models calculate a fair value of HK$2.37 per share.
What do the bullish and bearish scenarios say about 9886?
Our models span a range for Dingdang Health Tech Grp Ltd: cautious scenario HK$1.55, base HK$2.37, optimistic HK$3.56 per share (as of Oct 2, 2026, price HK$0.8000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dingdang Health Tech Grp Ltd (9886)?
Balance-sheet figures for Dingdang Health Tech Grp Ltd (as of Oct 2, 2026): return on equity −3.1%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is 9886 from its 52-week high?
Dingdang Health Tech Grp Ltd trades at HK$0.8000, about 36% below its 52-week high of HK$1.25 and 14% above the low of HK$0.7000 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.37 is for.
Which stocks are comparable to Dingdang Health Tech Grp Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dingdang Health Tech Grp Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price HK$0.8000, calculated fair value HK$2.37 (+196%), Quality Score 63/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9886 calculated?
We run Dingdang Health Tech Grp Ltd through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.37, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Dingdang Health Tech Grp Ltd currently trades 66 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dingdang Health Tech Grp Ltd (9886)?
The closing price on Sep 30, 2026 was HK$0.8000. Our model-based fair value is HK$2.37, about +196% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dingdang Health Tech Grp Ltd right now?
The price is below even our cautious bear case (HK$1.55). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$1.55 to HK$3.56) leaves room in how you read the outcome.
Key figures of Dingdang Health Tech Grp Ltd
How large is the market capitalisation of Dingdang Health Tech Grp Ltd (9886)?
The market capitalisation of Dingdang Health Tech Grp Ltd is HK$1.0B (≈ $128M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dingdang Health Tech Grp Ltd (9886)?
The price-to-sales ratio of Dingdang Health Tech Grp Ltd is 0.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Dingdang Health Tech Grp Ltd (9886)?
The net margin of Dingdang Health Tech Grp Ltd is −1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dingdang Health Tech Grp Ltd (9886)?
The return on equity (ROE) of Dingdang Health Tech Grp Ltd is −4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dingdang Health Tech Grp Ltd (9886)?
On an EBIT basis the return on assets of Dingdang Health Tech Grp Ltd is −9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dingdang Health Tech Grp Ltd (9886)?
The operating margin of Dingdang Health Tech Grp Ltd is 0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dingdang Health Tech Grp Ltd (9886)?
Revenue at Dingdang Health Tech Grp Ltd is growing +3.5% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Dingdang Health Tech Grp Ltd (9886) hold?
Dingdang Health Tech Grp Ltd holds more cash than debt, 175M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Dingdang Health Tech Grp Ltd in the live analysis
One click puts Dingdang Health Tech Grp Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
